These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 32197634)

  • 21. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
    Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
    Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
    Stankov K; Stankov S; Katanic J
    Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
    Harada H; Harada Y
    Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.
    Sarhan D; Brandt L; Felices M; Guldevall K; Lenvik T; Hinderlie P; Curtsinger J; Warlick E; Spellman SR; Blazar BR; Weisdorf DJ; Cooley S; Vallera DA; Önfelt B; Miller JS
    Blood Adv; 2018 Jun; 2(12):1459-1469. PubMed ID: 29941459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858.
    Eksioglu EA; Chen X; Heider KH; Rueter B; McGraw KL; Basiorka AA; Wei M; Burnette A; Cheng P; Lancet J; Komrokji R; Djeu J; List A; Wei S
    Leukemia; 2017 Oct; 31(10):2172-2180. PubMed ID: 28096534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of patients with lower-risk myelodysplastic syndromes.
    Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N
    Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computing cell state discriminates the aberrant hematopoiesis and activated microenvironment in Myelodysplastic syndrome (MDS) through a single cell genomic study.
    Guo X; Jin W; Wen Y; Wang Z; Ren X; Liu Z; Fu R; Cai Z; Li L
    J Transl Med; 2024 Jul; 22(1):673. PubMed ID: 39033303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men.
    Slape C; Lin YW; Hartung H; Zhang Z; Wolff L; Aplan PD
    J Natl Cancer Inst Monogr; 2008; (39):64-8. PubMed ID: 18648006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
    Nakajima H
    Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myelodysplastic syndromes: the pediatric point of view.
    Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F
    Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes.
    Han D; Tao J; Fu R; Shao Z
    Innate Immun; 2020 Nov; 26(8):703-715. PubMed ID: 33050756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innate immune signaling in the myelodysplastic syndromes.
    Starczynowski DT; Karsan A
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Immune Signaling Pathways in Clonal Hematopoiesis.
    Azrakhsh NA; Mensah-Glanowska P; Sand K; Kittang AO
    Curr Med Chem; 2019; 26(28):5262-5277. PubMed ID: 30907306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy-related myelodysplastic syndrome.
    Candelaria M; Dueñas-Gonzalez A
    Expert Opin Drug Saf; 2015 May; 14(5):655-65. PubMed ID: 25675961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanisms involved in the progression of myelodysplastic syndrome.
    Nolte F; Hofmann WK
    Future Oncol; 2010 Mar; 6(3):445-55. PubMed ID: 20222800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
    Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
    Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Over expression of mTOR gene predicts overall survival in myelodysplastic syndromes.
    Maurya N; Mohanty P; Panchal P; Shanmukhaiah C; Vundinti BR
    Mol Biol Rep; 2023 Jan; 50(1):235-244. PubMed ID: 36322239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
    Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR
    Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.